Chitosan Nanoparticle-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives

The effectiveness and uses of chitosan nanoparticles (CNPs) in drug delivery systems are examined in this work. Important results include the improved drug encapsulating efficiency: CNPs showed up to 90% encapsulation for different therapeutic agents. Furthermore, the research shows that CNPs provide extended-release patterns, greatly enhancing medication bioavailability especially for hydrophobic compounds. One interesting outcome was the greater drug stability in acidic surroundings, which are common in the stomach, where CNPs turn into a gel and later inflate in the intestine where the drug is released. Moreover, CNPs showed a 2-3-fold improvement in the absorption of encapsulated pharmaceuticals relative to traditional formulations, therefore indicating their capacity to overcome the problems of low oral bioavailability. These nanoparticles' pH-sensitive character produced a 50-70% increase in drug release at certain pH values, hence maximizing therapeutic results. Significantly less systemic toxicity was seen in the in vivo tests, and at therapeutic dosages there were no noted side effects. Histological study confirmed the biocompatibility and non-toxicity of CNPs, therefore attesting their fit for long-term usage. These results highlight the great potential of CNPs in providing effective, focused, continuous drug release, hence improving therapeutic effectiveness and patient compliance.